`Patent Owner’s Motion For Admission Pro Hac Vice Of Andrew J. Danford
`
`
`Filed on behalf of Patent Owner Genentech, Inc. by:
`
`
`David L. Cavanaugh (Reg. No. 36,476)
`
`Owen K. Allen (Reg. No. 71,118)
`
`Robert J. Gunther, Jr. (Pro Hac Vice pending)
`Lisa J. Pirozzolo (Pro Hac Vice pending)
`
`Kevin S. Prussia (Pro Hac Vice pending)
`
`Andrew J. Danford (Pro Hac Vice pending)
`WILMER CUTLER PICKERING
`
`
` HALE AND DORR LLP
`1875 Pennsylvania Ave., NW
`
`Washington, DC 20006
`
`
`Adam R. Brausa (Reg No.
`60,287
`Daralyn J. Durie (Pro Hac
`Vice pending)
`DURIE TANGRI LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`PFIZER, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`
`
`Case IPR2017-01488
`U.S. Patent 6,407,213
`
`
`PATENT OWNER’S UNOPPOSED MOTION FOR ADMISSION
`PRO HAC VICE OF ANDREW J. DANFORD
`
`
`
`
`
`Case No. IPR2017-01488
`Patent Owner’s Motion For Admission Pro Hac Vice Of Andrew J. Danford
`
`
`I. Statement of Precise Relief Requested
`
`Pursuant to 37 C.F.R. § 42.10(c), Patent Owner Genentech, Inc.
`
`(“Genentech”) requests that the Patent Trial and Appeal Board (the “Board”) admit
`
`Andrew J. Danford pro hac vice in this proceeding, IPR2017-01488. Petitioner
`
`Pfizer Inc. has indicated that it does not oppose this motion.
`
`II. Statement of Facts Showing Good Cause for the Board to Recognize
`Counsel Pro Hac Vice During the Proceeding
`In accordance with 37 C.F.R. § 42.10(c), the Board may recognize counsel
`
`pro hac vice during a proceeding upon a showing of good cause, subject to the
`
`condition that lead counsel be a registered practitioner and to any other conditions
`
`as the Board may impose. Section 42.10(c) indicates that “where lead counsel is a
`
`registered practitioner, a motion to appear pro hac vice by counsel who is not a
`
`registered practitioner may be granted upon a showing that counsel is an
`
`experienced litigating attorney and has an established familiarity with the subject
`
`matter at issue in the proceeding.” The facts here establish good cause for the
`
`Board to recognize Andrew J. Danford pro hac vice in this proceeding.
`
`1. Lead counsel, David L. Cavanaugh, is a registered practitioner. Backup
`
`counsel, Adam Brausa and Owen Allen are also registered practitioners.
`
`2. Counsel, Andrew J. Danford, is an experienced litigator and has an
`
`established familiarity with the subject matter at issue in the proceeding.
`
`
`
`- 2 -
`
`
`
`Case No. IPR2017-01488
`Patent Owner’s Motion For Admission Pro Hac Vice Of Andrew J. Danford
`
`
`Accompanying this motion as Exhibit 2038 is the Declaration of Andrew J.
`
`Danford in Support of this Motion for Admission Pro Hac Vice (“Danford
`
`Decl.”). In his declaration, Mr. Danford asserts:
`
`I am a member in good standing of the Massachusetts and New York
`
`Bars, and am admitted to practice before the United States District
`
`Court for the District of Massachusetts, the United States Court of
`
`Appeals for the First Circuit, and the United States Court of Appeals
`
`for the Federal Circuit.
`
`Danford Decl. ¶ 2 (Ex. 2038). Mr. Danford also demonstrates that he has a
`
`detailed working knowledge of the relevant subject matter through both
`
`prior inter partes review experience and his familiarity with antibody
`
`technologies as a result of participation as counsel in prior antibody-related
`
`patent cases. Danford Decl. ¶¶ 10-11 (Ex. 2038).
`
`3. In his declaration, Mr. Danford also attests to each of the listed items
`
`required by the Order – Authorizing Motion for Pro Hac Vice Admission –
`
`37 C.F.R. § 42.10 in IPR2013-00639. See Danford Decl. ¶¶ 1-12 (Ex.
`
`2038). Mr. Danford attests that he has read and will comply with the Office
`
`Patent Trial Practice Guide and the Board’s Rules of Practice for Trials set
`
`forth in 37 C.F.R. § 42. See id. ¶ 8. Mr. Danford further attests that he
`
`agrees to be subject to the United States Patent and Trademark Office’s
`
`
`
`- 3 -
`
`
`
`Case No. IPR2017-01488
`Patent Owner’s Motion For Admission Pro Hac Vice Of Andrew J. Danford
`
`Rules of Professional Conduct as set forth in 37 C.F.R. §§ 11.101 et seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a). See id. ¶ 9.
`
`III. Conclusion
`
`For the foregoing reasons, Patent Owner respectfully requests that the Board
`
`admit Andrew J. Danford pro hac vice in this proceeding.
`
`Date: September 20, 2017
`
`Respectfully submitted,
`
`By: /David L. Cavanaugh/
`David L. Cavanaugh
`Reg. No. 36,476
`Wilmer Cutler Pickering Hale and Dorr LLP
`1875 Pennsylvania Avenue NW
`Washington, DC 20006
`
`
`
`- 4 -
`
`
`
`Case No. IPR2017-01488
`Patent Owner’s Motion For Admission Pro Hac Vice Of Andrew J. Danford
`
`
`PATENT OWNER’S EXHIBIT LIST
`IPR2017-01488
`
`
`Patent Owner’s
`Exhibit Number
`2001
`
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit Name
`
`Genentech, Inc. Laboratory Notebook No. 10098 (Leonard
`Presta)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 10823 (Leonard
`Presta)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11268 (Paul Carter)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11643 (Paul Carter)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 10840 (John Brady)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11162 (John Brady)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11008
`(Ann Rowland)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11297
`(Tim Hotaling)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11568
`(Monique Carver)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum from Paul Carter to
`Leonard Presta and Dennis Henner
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum from Paul Carter to
`Leonard Presta
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Synthetic DNA Requests
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Synthetic DNA Requests
`PROTECTIVE ORDER MATERIAL
`
`
`
`- i -
`
`
`
`Patent Owner’s
`Exhibit Number
`2014
`
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`2020
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2017-01488
`Patent Owner’s Motion For Admission Pro Hac Vice Of Andrew J. Danford
`
`
`Exhibit Name
`
`Genentech, Inc. Protein Engineering of 4D5 Status Report
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum re: RCC Minutes and
`Recommendations
`PROTECTIVE ORDER MATERIAL
`Declaration of Dr. Leonard G. Presta
`PROTECTIVE ORDER MATERIAL
`Declaration of Dr. Paul J. Carter
`PROTECTIVE ORDER MATERIAL
`Declaration of John Ridgway Brady
`PROTECTIVE ORDER MATERIAL
`Declaration of Irene Loeffler
`Paul Carter, et al., Humanization of the Anti-p185 Antibody for
`Human Cancer Therapy, 89 PROC. NATL. ACAD. SCI. 4285-
`4289 (1992)
`Leonard Presta, et al., Humanization of an Anti-Vascular
`Endothelial Growth Factor Monoclonal Antibody for the
`Therapy of Solid Tumors and Other Disorders, 57 CANCER
`RESEARCH 4593-4599 (1997)
`Marianne Brüggerman, et al., The Immunogenicity of Chimeric
`Antibodies, 170 J. EXP. MED. 2153-2157 (1989)
`Jatinderpal Kalsi, et al., Structure-function Analysis and the
`Molecular Origins of Anti-DNA Antibodies in Systemic Lupus
`Erythematosus, EXPERT REVIEWS IN MOLECULAR MEDICINE 1-
`28 (1999)
`Scott Gorman, et al., Reshaping a Therapeutic CD4 Antibody,
`88 PROC. NATL. ACAD. SCI. 4181-4185 (1991)
`John Isaacs, et al., Humanised Monoclonal Antibody Therapy
`for Rheumatoid Arthritis, 340 THE LANCET 748-752 (1992)
`Elvin Kabat, et al., Sequences of Proteins of Immunological
`Interest 1-23 (4th ed. 1987)
`Anna Tramontano, et al., Framework Residue 71 Is a Major
`Determinant of the Position and Conformation of the Second
`Hypervariable Region in the VH Domains of Immunoglobulins,
`215 J. MOL. BIOL. 175-182 (1990)
`
`
`
`- ii -
`
`
`
`Case No. IPR2017-01488
`Patent Owner’s Motion For Admission Pro Hac Vice Of Andrew J. Danford
`
`
`Exhibit Name
`
`H.M. Shepard, et al., Herceptin, in THERAPEUTIC ANTIBODIES.
`HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 183-219 (Y.
`Chernajovsky & A. Nissim, eds. 2008)
`Excerpt from Roche Finance Report 2016
`Modified Default Standing Protective Order and Patent
`Owner’s Certification of Agreement to Terms
`Modified Default Standing Protective Order – Redline
`File History for U.S. Patent Application No. 07/715,272
`Immunoglobulin Variants (filed June 14, 1991).
`Shearman, et al. Construction, expression and characterization
`of humanized antibodies directed against the human a/b T cell
`receptor. J. Immunol. 147(12):4366-4373, (December 15,
`1991)
`Declaration of Robert J. Gunther, Jr. in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Daralyn J. Durie in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Lisa J. Pirozzolo in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Kevin S. Prussia in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Andrew J. Danford in Support of Motion for
`Admission Pro Hac Vice
`
`
`
`
`
`
`
`- iii -
`
`Patent Owner’s
`Exhibit Number
`2028
`
`
`2029
`2030
`
`2031
`2032
`
`2033
`
`2034
`
`2035
`
`2036
`
`2037
`
`2038
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2017-01488
`Patent Owner’s Motion For Admission Pro Hac Vice Of Andrew J. Danford
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that, on September 22, 2017, I caused a true and correct
`copy of the following materials:
`
`
`
` Patent Owner’s Unopposed Motion for Admission Pro Hac Vice of
`Andrew J. Danford
`
` Exhibit 2038
`
`
`
` Patent Owner’s Exhibit List
`
`to be served via electronic mail on the following attorneys of record:
`
`Amanda Hollis
`KIRKLAND & ELLIS LLP
`amanda.hollis@kirkland.com
`300 North LaSalle, Chicago, IL 60654
`
`Stefan M. Miller, Ph.D.
`Stefan.miller@kirkland.com
` 601 Lexington Avenue, New York, NY 10022
`
`Karen Younkins
`karen.younkins@kirkland.com
`333 South Hope Street, Los Angeles, CA 90071
`
`Pfizer_Genentech_IPRs@kirkland.com
`
`
`/Rebecca A. Whitfield/
`Rebecca A. Whitfield
`Reg. No. 73,756
`Wilmer Cutler Pickering Hale and Dorr LLP
`60 State Street
`Boston, MA 02109
`(617) 526-5566
`
`- iv -
`
`
`
`
`
`ActiveUS 164772623v.1
`
`